Frazier Life Sciences Management
Latest statistics and disclosures from Frazier Life Sciences Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are MIRM, NAMS, VRNA, BBIO, ARQT, and represent 51.54% of Frazier Life Sciences Management's stock portfolio.
- Added to shares of these 10 stocks: ABVX (+$32M), CYTK (+$19M), DYN (+$15M), ACAD (+$13M), ASMB (+$12M), MBX (+$12M), ZLAB (+$11M), VALN (+$10M), ENGN (+$7.9M), ADVM.
- Started 4 new stock positions in ENGN, ASMB, ABVX, ACAD.
- Reduced shares in these 10 stocks: Hillevax (-$21M), CGON (-$20M), TVTX (-$15M), IRON (-$14M), TARS (-$14M), COGT (-$13M), ORIC (-$11M), ALKS (-$9.0M), ORKA (-$6.5M), JBIO.
- Sold out of its positions in CGON, COGT, ELEV, Hillevax, ORIC, ORKA.
- Frazier Life Sciences Management was a net buyer of stock by $14M.
- Frazier Life Sciences Management has $3.3B in assets under management (AUM), dropping by 33.46%.
- Central Index Key (CIK): 0001892134
Tip: Access up to 7 years of quarterly data
Positions held by Frazier Life Sciences Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Frazier Life Sciences Management
Frazier Life Sciences Management holds 47 positions in its portfolio as reported in the September 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Mirum Pharmaceuticals (MIRM) | 14.9 | $498M | 6.8M | 73.31 |
|
|
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 14.2 | $475M | 17M | 28.44 |
|
|
| Verona Pharma Sponsored Ads (VRNA) | 10.8 | $361M | 3.4M | 106.71 |
|
|
| Bridgebio Pharma (BBIO) | 6.0 | $200M | 3.8M | 51.94 |
|
|
| Arcutis Biotherapeutics (ARQT) | 5.6 | $186M | 9.9M | 18.85 |
|
|
| Phathom Pharmaceuticals (PHAT) | 4.4 | $147M | 13M | 11.77 |
|
|
| Krystal Biotech (KRYS) | 3.6 | $122M | 689k | 176.53 |
|
|
| Maze Therapeatics (MAZE) | 3.5 | $118M | 4.6M | 25.93 |
|
|
| Mbx Biosciences (MBX) | 3.5 | $116M | +11% | 6.7M | 17.50 |
|
| Disc Medicine (IRON) | 2.8 | $95M | -13% | 1.4M | 66.08 |
|
| Trevi Therapeutics (TRVI) | 2.8 | $94M | 10M | 9.15 |
|
|
| Tarsus Pharmaceuticals (TARS) | 2.1 | $69M | -16% | 1.2M | 59.43 |
|
| Kalvista Pharmaceuticals (KALV) | 1.8 | $61M | +3% | 5.0M | 12.18 |
|
| Zai Lab Adr (ZLAB) | 1.7 | $55M | +24% | 1.6M | 33.89 |
|
| Agios Pharmaceuticals (AGIO) | 1.5 | $51M | 1.3M | 40.14 |
|
|
| Erasca (ERAS) | 1.5 | $50M | 23M | 2.18 |
|
|
| Cytokinetics Com New (CYTK) | 1.5 | $49M | +60% | 890k | 54.96 |
|
| Revolution Medicines (RVMD) | 1.4 | $47M | 998k | 46.70 |
|
|
| Palvella Therapeutics Inc Ne (PVLA) | 1.4 | $45M | 722k | 62.69 |
|
|
| Savara (SVRA) | 1.2 | $41M | 12M | 3.57 |
|
|
| Dyne Therapeutics (DYN) | 1.0 | $34M | +80% | 2.7M | 12.65 |
|
| Abivax Sa Sponsored Ads (ABVX) | 1.0 | $32M | NEW | 378k | 84.90 |
|
| Aura Biosciences (AURA) | 0.9 | $32M | 5.1M | 6.18 |
|
|
| Ultragenyx Pharmaceutical (RARE) | 0.9 | $30M | 984k | 30.08 |
|
|
| Lexeo Therapeutics (LXEO) | 0.9 | $29M | 4.4M | 6.64 |
|
|
| Valneva Se Sponsored Ads (VALN) | 0.8 | $28M | +57% | 2.3M | 12.20 |
|
| Avidity Biosciences Ord (RNA) | 0.8 | $27M | 625k | 43.57 |
|
|
| Ascendis Pharma A/s Sponsored Adr (ASND) | 0.8 | $27M | 133k | 198.81 |
|
|
| Alkermes SHS (ALKS) | 0.6 | $21M | -29% | 701k | 30.00 |
|
| Mereo Biopharma Group Spon Ads (MREO) | 0.6 | $19M | 9.4M | 2.06 |
|
|
| Akero Therapeutics (AKRO) | 0.5 | $17M | 367k | 47.48 |
|
|
| Vaxcyte (PCVX) | 0.5 | $17M | 474k | 36.02 |
|
|
| Evolus (EOLS) | 0.5 | $16M | +8% | 2.6M | 6.14 |
|
| Design Therapeutics (DSGN) | 0.4 | $15M | 2.0M | 7.53 |
|
|
| Immunocore Hldgs Ads (IMCR) | 0.4 | $14M | 385k | 36.33 |
|
|
| ACADIA Pharmaceuticals (ACAD) | 0.4 | $13M | NEW | 614k | 21.34 |
|
| Jade Biosciences Com New (JBIO) | 0.4 | $12M | -20% | 1.4M | 8.63 |
|
| Assembly Biosciences Com New (ASMB) | 0.3 | $12M | NEW | 456k | 25.60 |
|
| Adverum Biotechnologies Com New (ADVM) | 0.3 | $9.4M | +94% | 2.1M | 4.53 |
|
| Travere Therapeutics (TVTX) | 0.3 | $9.4M | -60% | 392k | 23.90 |
|
| Newamsterdam Pharma Company *w Exp 99/99/999 (NAMSW) | 0.3 | $8.6M | 500k | 17.11 |
|
|
| Engene Holdings (ENGN) | 0.2 | $7.9M | NEW | 1.2M | 6.83 |
|
| Autolus Therapeutics Spon Ads (AUTL) | 0.2 | $7.5M | 4.6M | 1.63 |
|
|
| Macrogenics (MGNX) | 0.2 | $5.3M | 3.2M | 1.68 |
|
|
| Silence Therapeutics Ads (SLN) | 0.2 | $5.0M | 970k | 5.19 |
|
|
| Allogene Therapeutics (ALLO) | 0.1 | $4.8M | 3.9M | 1.24 |
|
|
| Crescent Biopharma (CBIO) | 0.1 | $3.2M | -39% | 273k | 11.89 |
|
Past Filings by Frazier Life Sciences Management
SEC 13F filings are viewable for Frazier Life Sciences Management going back to 2022
- Frazier Life Sciences Management 2025 Q3 filed Nov. 14, 2025
- Frazier Life Sciences Management 2025 Q2 filed Aug. 14, 2025
- Frazier Life Sciences Management 2025 Q1 filed May 15, 2025
- Frazier Life Sciences Management 2024 Q4 filed Feb. 18, 2025
- Frazier Life Sciences Management 2024 Q3 filed Nov. 15, 2024
- Frazier Life Sciences Management 2024 Q2 filed Aug. 15, 2024
- Frazier Life Sciences Management 2024 Q1 filed May 15, 2024
- Frazier Life Sciences Management 2023 Q4 filed Feb. 14, 2024
- Frazier Life Sciences Management 2023 Q3 filed Nov. 14, 2023
- Frazier Life Sciences Management 2023 Q2 filed Aug. 14, 2023
- Frazier Life Sciences Management 2023 Q1 filed May 15, 2023
- Frazier Life Sciences Management 2022 Q4 restated filed Feb. 7, 2023
- Frazier Life Sciences Management 2022 Q4 filed Feb. 3, 2023
- Frazier Life Sciences Management 2022 Q3 filed Nov. 14, 2022
- Frazier Life Sciences Management 2022 Q2 filed Aug. 10, 2022
- Frazier Life Sciences Management 2022 Q1 filed May 16, 2022